AstraZeneca, Bristol Myers Squibb Hold Preliminary Talks on Potential $400 Billion Pharma Merger

LONDON: British pharmaceutical giant AstraZeneca has held preliminary discussions with U.S.-based Bristol Myers Squibb over a potential merger that could create one of the world’s largest drugmakers with a combined market value of nearly $400 billion, according to a source familiar with the matter.

The talks, first reported by the Financial Times, remain at an early stage, and it is unclear whether negotiations are continuing or will ultimately result in a transaction. Neither AstraZeneca nor Bristol Myers Squibb has publicly commented on the reported discussions.

A merger between the two pharmaceutical companies would significantly strengthen AstraZeneca’s presence in the United States while combining two of the industry’s leading oncology portfolios. However, analysts say such a deal would face intense scrutiny from U.S. antitrust regulators because of overlapping cancer treatments and other product lines, potentially requiring major asset divestitures.

AstraZeneca has enjoyed strong growth in recent years, driven by its cancer and rare disease medicines, and has set an ambitious target of reaching $80 billion in annual revenue by 2030. Bristol Myers Squibb, meanwhile, has been seeking new growth opportunities as several of its blockbuster medicines approach patent expirations, despite recently raising its 2026 financial outlook following stronger-than-expected quarterly results.

The proposed combination would rank among the largest pharmaceutical mergers in history and underscore continued consolidation in the global healthcare sector. Industry observers note, however, that regulatory hurdles and political considerations on both sides of the Atlantic could complicate any agreement, making the outcome of the discussions uncertain.